LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Investigation of the biofilm formation in extra-intestinal pathogenic Escherichia coli ST131 strains and its correlation with the presence of fimH, afa, and kpsMSTII genes.

    Ebrahimi, Mohammad Taha / Hedayati, Manouchehr Ahmadi / Pirlar, Rima Fanaei / Mortazavi, Newsha / Nazari, Mohsen / Ahmadi, Amjad / Hemmati, Jaber / Erfani, Yousef

    Journal of applied genetics

    2023  Volume 64, Issue 2, Page(s) 367–373

    Abstract: Escherichia coli sequence type 131 (ST131) is a multidrug-resistant strain with the global dissemination. Biofilm formation-related factors include the most important virulence factors in extra-intestinal pathogenic E. coli (ExPEC) ST131 strains causing ... ...

    Abstract Escherichia coli sequence type 131 (ST131) is a multidrug-resistant strain with the global dissemination. Biofilm formation-related factors include the most important virulence factors in extra-intestinal pathogenic E. coli (ExPEC) ST131 strains causing infections with treatment-limited subjects. This study aims to investigate the biofilm formation ability and its correlation with the presence of fimH, afa, and kpsMSTII genes in clinical isolates of ExPEC ST131. In this regard, the prevalence and characteristics of these strains collected and evaluated. The results revealed strong, moderate, and weak attachment abilities related to biofilm formation attributes in 45%, 20%, and 35% of strains, respectively. In the meantime, the frequency of the fimH, afa, and kpsMSTII genes among the isolates was observed as follows: fimH positive: 65%; afa positive: 55%; and kpsMSTII positive: 85%. The results convey a significant different of biofilm formation ability between clinical E. coli ST131 and non-ST131 isolates. Furthermore, while 45% of ST131 isolates produced strong biofilms, only 2% of non-ST131 isolates showed the ability to form strong biofilms. The attending of fimH, afa, and kpsMSTII genes in the majority of ST131 strains demonstrated a key role leading to biofilm formation. These findings suggested the application of fimH, afa, and kpsMSTII gene suppressors for treating biofilm infections caused by drug-resistant ST131 strains.
    MeSH term(s) Humans ; Escherichia coli/genetics ; Escherichia coli Infections ; Virulence Factors/genetics ; Biofilms ; Anti-Bacterial Agents ; Adhesins, Escherichia coli/genetics ; Fimbriae Proteins/genetics ; Fimbriae Proteins/therapeutic use
    Chemical Substances Virulence Factors ; Anti-Bacterial Agents ; fimH protein, E coli ; Adhesins, Escherichia coli ; Fimbriae Proteins (147680-16-8)
    Language English
    Publishing date 2023-03-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 1235302-4
    ISSN 2190-3883 ; 1234-1983
    ISSN (online) 2190-3883
    ISSN 1234-1983
    DOI 10.1007/s13353-023-00757-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A

    Sadatpour, Omid / Ebrahimi, Mohammad Taha / Akhtari, Maryam / Ahmadzadeh, Nooshin / Vojdanian, Mahdi / Jamshidi, Ahmadreza / Farhadi, Elham / Mahmoudi, Mahdi

    BMC musculoskeletal disorders

    2022  Volume 23, Issue 1, Page(s) 908

    Abstract: Background: Ankylosing spondylitis (AS) is an inflammatory autoimmune disease that mostly affects different joints of the body. Macrophages are the predominant cells that mediate disease progression by secreting several pro-inflammatory mediators. ... ...

    Title translation Authors and affiliations.
    Abstract Background: Ankylosing spondylitis (AS) is an inflammatory autoimmune disease that mostly affects different joints of the body. Macrophages are the predominant cells that mediate disease progression by secreting several pro-inflammatory mediators. Different receptors are involved in macrophages' function including the adenosine receptors (AR). Our main objective in this study was to assess the effect of applying A
    Methods: Monocytes were isolated from the whole blood of 28 individuals (AS patients and healthy controls in a 1:1 ratio). Macrophages were differentiated using macrophage colony-stimulating factor (M-CSF), and flow cytometry was performed to confirm surface markers. CGS-21,680 was used to treat cells that had been differentiated. Using SYBR green real-time PCR, relative gene expression was determined.
    Results: Activating A
    Conclusion: Due to the disability of A
    MeSH term(s) Bone Morphogenetic Proteins ; Humans ; Inflammation Mediators/metabolism ; Macrophage Colony-Stimulating Factor ; Macrophages/metabolism ; Matrix Metalloproteinase 8/metabolism ; Matrix Metalloproteinase 9 ; Purinergic P1 Receptor Agonists/metabolism ; Receptors, Purinergic P1/metabolism ; Severity of Illness Index ; Spondylitis, Ankylosing/drug therapy
    Chemical Substances Bone Morphogenetic Proteins ; Inflammation Mediators ; Purinergic P1 Receptor Agonists ; Receptors, Purinergic P1 ; Macrophage Colony-Stimulating Factor (81627-83-0) ; MMP8 protein, human (EC 3.4.24.34) ; Matrix Metalloproteinase 8 (EC 3.4.24.34) ; Matrix Metalloproteinase 9 (EC 3.4.24.35)
    Language English
    Publishing date 2022-10-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041355-5
    ISSN 1471-2474 ; 1471-2474
    ISSN (online) 1471-2474
    ISSN 1471-2474
    DOI 10.1186/s12891-022-05846-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.

    Aghamiri, Shahin / Raee, Pourya / Shahmohamadnejad, Shiva / Shabani, Sasan / Ghorbani, Jaber / Sameni, Marzieh / Ebrahimi, Mohammad Taha

    Current pharmaceutical biotechnology

    2021  Volume 23, Issue 4, Page(s) 579–593

    Abstract: The critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle- based siRNA therapeutics. Unfortunately, siRNA-based ... ...

    Abstract The critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle- based siRNA therapeutics. Unfortunately, siRNA-based therapeutics suffer from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical translation, and commercialization. In this review, we provide cutting-edge advances in nanoparticle-mediated siRNA delivery carriers like polymeric systems, lipid systems, specific systems, and rigid nanoparticles for the treatment of prostate cancer. Moreover, co-delivery of conventional chemotherapy drugs with siRNA as a revolutionary robust strategy for prostate cancer combinational therapy is completely covered.
    MeSH term(s) Drug Delivery Systems ; Humans ; Lipids ; Male ; Nanoparticles ; Neoplasms ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/therapy ; RNA, Small Interfering/genetics
    Chemical Substances Lipids ; RNA, Small Interfering
    Language English
    Publishing date 2021-06-15
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2132197-8
    ISSN 1873-4316 ; 1389-2010
    ISSN (online) 1873-4316
    ISSN 1389-2010
    DOI 10.2174/1389201022666210615123211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top